Molecular determinants of blood–brain barrier permeation

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Ghose AK, Herbertz T, Hudkins RL, Dorsey BD, Mallamo JP. Knowledge-based, central nervous system (CNS) lead selection and lead optimization for CNS drug discovery. ACS Chem. Neurosci. 3(1), 50–68 (2012).
  Medline CASGoogle Scholar
• 2 Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the united states (2010–2050) estimated using the 2010 census. Neurology 80(19), 1778–1783 (2013).
  MedlineGoogle Scholar
• 3 Wenlock MC, Austin RP, Barton P, Davis AM, Leeson PD. A comparison of physiochemical property profiles of development and marketed oral drugs. J. Med. Chem. 46(7), 1250–1256 (2003).
  Medline CASGoogle Scholar
• 4 Ortwine DF, Aliagas I. Physicochemical and dmpk in silico models: facilitating their use by medicinal chemists. Mol. Pharm. 10(4), 1153–1161 (2013).
  Medline CASGoogle Scholar
• 5 Meanwell NA. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. Chem. Res. Toxicol. 24(9), 1420–1456 (2011).
  Medline CASGoogle Scholar
• 6 Pardridge WM. blood–brain barrier delivery. Drug Discov. Today 12(1–2), 54–61 (2007).
  Medline CASGoogle Scholar
• 7 Hitchcock SA. blood–brain barrier permeability considerations for CNS-targeted compound library design. Curr. Opin. Chem. Biol. 12(3), 318–323 (2008).
  Medline CASGoogle Scholar
• 8 Abbott NJ. blood–brain barrier structure and function and the challenges for cns drug delivery. J. Inherit. Metabol. Dis. 36(3), 437–449 (2013).
  Medline CASGoogle Scholar
• 9 Devraj K, Klinger ME, Myers RL, Mokashi A, Hawkins RA, Simpson IA. GLUT-1 glucose transporters in the blood–brain barrier: differential phosphorylation. J. Neurosci. Res. 89(12), 1913–1925 (2011).
  Medline CASGoogle Scholar
• 10 Gagliardi M, Bardi G, Bifone A. Polymeric nanocarriers for controlled and enhanced delivery of therapeutic agents to the cns. Ther. Deliv. 3(7), 875–887 (2012).
  CASGoogle Scholar
• 11 Boado RJ, Hui EK, Lu JZ, Pardridge WM. IGG-enzyme fusion protein: pharmacokinetics and anti-drug antibody response in rhesus monkeys. Bioconjug. Chem. 24(1), 97–104 (2013).
  Medline CASGoogle Scholar
• 12 Ribatti D, Nico B, Crivellato E, Artico M. Development of the blood–brain barrier: a historical point of view. Anat. Rec. B New Anat. 289(1), 3–8 (2006).
  MedlineGoogle Scholar
• 13 Lai CH, Kuo KH. The critical component to establish in vitro bbb model: pericyte. Brain Res. Brain Res. Rev. 50(2), 258–265 (2005).
  Medline CASGoogle Scholar
• 14 Pardridge WM. blood–brain barrier biology and methodology. J. Neurovirol. 5(6), 556–569 (1999).
  Medline CASGoogle Scholar
• 15 Cohen Z, Ehret M, Maitre M, Hamel E. Ultrastructural analysis of tryptophan hydroxylase immunoreactive nerve terminals in the rat cerebral cortex and hippocampus: their associations with local blood vessels. Neuroscience 66(3), 555–569 (1995).
  Medline CASGoogle Scholar
• 16 Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood–brain barrier. Neurobiol. Dis. 37(1), 13–25 (2010).• Describes structure and function of blood–brain barrier (BBB) and explains the pitfalls in CNS drug delivery.
  Medline CASGoogle Scholar
• 17 Loscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat. Rev. Neurosci. 6(8), 591–602 (2005).
  MedlineGoogle Scholar
• 18 Loscher W, Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog. Neurobiol. 76(1), 22–76 (2005).
  MedlineGoogle Scholar
• 19 Manda VK, Mittapalli RK, In situ WJ, Lockman PR. Chronic exposure to nicotine and saquinavir decreases endothelial notch-4 expression and disrupts blood–brain barrier integrity. J. Neurochem. 115(2), 515–525 (2010).
  Medline CASGoogle Scholar
• 20 Kalvass JC, Polli JW, Bourdet DL et al. Why clinical inhibition of efflux transport at the blood–brain barrier is unlikely: the ITC evidence-based position. Clin. Pharmacol. Ther. 94(1), 80–94 (2013).
  Medline CASGoogle Scholar
• 21 Correale J, Villa A. Cellular elements of the blood–brain barrier. Neurochem. Res. 34(12), 2067–2077 (2009).
  Medline CASGoogle Scholar
• 22 Stamatovic SM, Keep RF, Andjelkovic AV. Brain endothelial cell–cell junctions: how to “open” the blood brain barrier. Curr. Neuropharmacol. 6(3), 179–192 (2008).
  Medline CASGoogle Scholar
• 23 Konofagou EE. Optimization of the ultrasound-induced blood–brain barrier opening. Theranostics 2(12), 1223–1237 (2012).
  Medline CASGoogle Scholar
• 24 Martin JA, Maris AS, Ehtesham M, Singer RJ. Rat model of blood–brain barrier disruption to allow targeted neurovascular therapeutics. J. Vis. Exp. 30(69), e50019 (2012).
  Google Scholar
• 25 Nagaraja TN, Karki K, Ewing JR, Croxen RL, Knight RA. Identification of variations in blood–brain barrier opening after cerebral ischemia by dual contrast-enhanced magnetic resonance imaging and T 1SAT measurements. Stroke 39(2), 427–432 (2008).
  MedlineGoogle Scholar
• 26 Bahadduri PM, Polli JE, Swaan PW, Ekins S. Targeting drug transporters ‐ combining in silico and in vitro approaches to predict in vivo. Methods Mol. Biol. 637, 65–103 (2010).
  Medline CASGoogle Scholar
• 27 Mittapalli RK, Manda VK, Adkins CE, Geldenhuys WJ, Lockman PR. Exploiting nutrient transporters at the blood–brain barrier to improve brain distribution of small molecules. Ther. Deliv. 1(6), 775–784 (2010).
  CASGoogle Scholar
• 28 In situ WJ, Allen DD. The blood–brain barrier choline transporter. Cent. Nerv. Syst. Agents Med. Chem. 12(2), 95–99 (2012).
  MedlineGoogle Scholar
• 29 In situ WJ, Allen DD, Bloomquist JR. Novel models for assessing blood–brain barrier drug permeatiobn. Expert Opin. Drug Metabol. Toxicol. 8(6), 647–653 (2012).
  MedlineGoogle Scholar
• 30 Murakami H, Takanaga H, Matsuo H, Ohtani H, Sawada Y. Comparison of blood–brain barrier permeability in mice and rats using in situ brain perfusion technique. Am. J. Physiol. Heart Circ. Physiol. 279(3), H1022–H1028 (2000).
  Medline CASGoogle Scholar
• 31 Rankovic Z. CNS drug design: balancing physicochemical properties for optimal brain exposure. J. Med. Chem. 58(6), 2584–608 (2015).
  Medline CASGoogle Scholar
• 32 Bickel U. How to measure drug transport across the blood–brain barrier. NeuroRx 2(1), 15–26 (2005).
  MedlineGoogle Scholar
• 33 Wohnsland F, Faller B. High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. J. Med. Chem. 44(6), 923–930 (2001).
  Medline CASGoogle Scholar
• 34 Kansy M, Senner F, Gubernator K. Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. J. Med. Chem. 41(7), 1007–1010 (1998).
  Medline CASGoogle Scholar
• 35 Fischer H, Kansy M, Avdeef A, Senner F. Permeation of permanently positive charged molecules through artificial membranes – influence of physico-chemical properties. Eur. J. Pharm. Sci. 31(1), 32–42 (2007).
  Medline CASGoogle Scholar
• 36 Wuest DM, Wing AM, Lee KH. Membrane configuration optimization for a murine in vitro blood–brain barrier model. J. Neurosci. Methods 212(2), 211–221 (2013).
  Medline CASGoogle Scholar
• 37 Hellinger E, Veszelka S, Toth AE et al. Comparison of brain capillary endothelial cell-based and epithelial (MDCK-MDR1, Caco-2, and VB-Caco-2) cell-based surrogate blood–brain barrier penetration models. Eur. J. Pharm. Biopharm. 82(2), 340–351 (2012).
  Medline CASGoogle Scholar
• 38 Kamiichi A, Furihata T, Kishida S et al. Establishment of a new conditionally immortalized cell line from human brain microvascular endothelial cells: a promising tool for human blood–brain barrier studies. Brain Res. 1488, 113–122 (2012).
  Medline CASGoogle Scholar
• 39 Roux F, Couraud PO. Rat brain endothelial cell lines for the study of blood–brain barrier permeability and transport functions. Cell. Mol. Neurobiol. 25(1), 41–58 (2005).
  MedlineGoogle Scholar
• 40 Weksler B, Romero IA, Couraud PO. The hcmec/d3 cell line as a model of the human blood brain barrier. Fluids Barriers CNS 10(1), 16 (2013).
  MedlineGoogle Scholar
• 41 Mateus A, Matsson P, Artursson P. A high-throughput cell-based method to predict the unbound drug fraction in the brain. J. Med. Chem. 57(7), 3005–3010 (2014).
  Medline CASGoogle Scholar
• 42 Mateus A, Matsson P, Artursson P. Rapid measurement of intracellular unbound drug concentrations. Mol. Pharm. 10(6), 2467–2478 (2013).
  Medline CASGoogle Scholar
• 43 Andersson O, Hansen SH, Hellman K et al. The grasshopper: a novel model for assessing vertebrate brain uptake. J. Pharmacol. Exp. Ther. 346(2), 211–218 (2013).
  Medline CASGoogle Scholar
• 44 Nielsen PA, Andersson O, Hansen SH, Simonsen KB, Andersson G. Models for predicting blood–brain barrier permeation. Drug Discov. Today 16(11–12), 472–475 (2011).
  Medline CASGoogle Scholar
• 45 Watanabe K, Nishimura Y, Nomoto T et al. In vivo assessment of the permeability of the blood–brain barrier and blood–retinal barrier to fluorescent indoline derivatives in zebrafish. BMC Neurosci. 13, 101 (2012).
  Medline CASGoogle Scholar
• 46 Jeong JY, Kwon HB, Ahn JC et al. Functional and developmental analysis of the blood–brain barrier in zebrafish. Brain Res. Bull. 75(5), 619–628 (2008).
  Medline CASGoogle Scholar
• 47 Takasato Y, Rapoport SI, Smith QR. An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am. J. Physiol. 247(3 Pt 2), H484–H493 (1984).• Describes in situ brain perfusion technique.
  Medline CASGoogle Scholar
• 48 Suenderhauf C, Hammann F, Huwyler J. Computational prediction of blood–brain barrier permeability using decision tree induction. Molecules 17(9), 10429–10445 (2012).
  Medline CASGoogle Scholar
• 49 Pardridge WM. Log(BB), PS products and in silico models of drug brain penetration. Drug Discov. Today 9(9), 392–393 (2004).• Describes log BBB and logPS.
  MedlineGoogle Scholar
• 50 Clark DE. In silico prediction of blood–brain barrier permeation. Drug Discov. Today 8(20), 927–933 (2003).
  Medline CASGoogle Scholar
• 51 Tewes BJ, Galla HJ. Lipid polarity in brain capillary endothelial cells. Endothelium 8(3), 207–220 (2001).
  Medline CASGoogle Scholar
• 52 Nitz T, Eisenblatter T, Psathaki K, Galla HJ. Serum-derived factors weaken the barrier properties of cultured porcine brain capillary endothelial cells in vitro. Brain Res. 981(1–2), 30–40 (2003).• Discusses in vitro BBB model utilizing porcine brain capillary endothelial cells.
  Medline CASGoogle Scholar
• 53 Wager TT, Hou X, Verhoest PR, Villalobos A. Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. ACS Chem. Neurosci. 1(6), 435–449 (2010).
  Medline CASGoogle Scholar
• 54 Hawkins PC, Nicholls A. Conformer generation with omega: learning from the data set and the analysis of failures. J. Chem. Inform. Model. 52(11), 2919–2936 (2012).
  Medline CASGoogle Scholar
• 55 Loryan I, Sinha V, Mackie C et al. Molecular properties determining unbound intracellular and extracellular brain exposure of CNS drug candidates. Mol. Pharm. 12(2), 520–532 (2014).
  MedlineGoogle Scholar
• 56 Wager TT, Chandrasekaran RY, Hou X et al. Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes. ACS Chem. Neurosci. 1(6), 420–434 (2010).
  Medline CASGoogle Scholar
• 57 Allen DD, Smith QR. Characterization of the blood–brain barrier choline transporter using the in situ rat brain perfusion technique. J. Neurochem. 76(4), 1032–1041 (2001).
  Medline CASGoogle Scholar
• 58 Gratton JA, Abraham MH, Bradbury MW, Chadha HS. Molecular factors influencing drug transfer across the blood–brain barrier. J. Pharm. Pharmaol. 49(12), 1211–1216 (1997).
  Medline CASGoogle Scholar
• 59 Liu X, Tu M, Kelly RS, Chen C, Smith BJ. Development of a computational approach to predict blood–brain barrier permeability. Drug Metab. Dispos. 32(1), 132–139 (2004).
  Medline CASGoogle Scholar
• 60 Dagenais C, Avdeef A, Tsinman O, Dudley A, Beliveau R. P-glycoprotein deficient mouse in situ blood–brain barrier permeability and its prediction using an in combo pampa model. Eur. J. Pharm. Sci. 38(2), 121–137 (2009).
  Medline CASGoogle Scholar
• 61 Ooms F, Weber P, Carrupt PA, Testa B. A simple model to predict blood–brain barrier permeation from 3D molecular fields. Biochim. Biophys. Acta 1587(2–3), 118–125 (2002).
  Medline CASGoogle Scholar
• 62 Crivori P, Cruciani G, Carrupt PA, Testa B. Predicting blood–brain barrier permeation from three-dimensional molecular structure. J. Med. Chem. 43(11), 2204–2216 (2000).
  Medline CASGoogle Scholar
• 63 Luco JM. Prediction of the brain–blood distribution of a large set of drugs from structurally derived descriptors using partial least-squares (PLS) modeling. J. Chem. Inform. Comput. Sci. 39(2), 396–404 (1999).
  Medline CASGoogle Scholar
• 64 Hutter MC. Prediction of blood–brain barrier permeation using quantum chemically derived information. J. Comput. Aid. Mol. Dis. 17(7), 415–433 (2003).
  Medline CASGoogle Scholar
• 65 Keseru GM, Molnar L. High-throughput prediction of blood–brain partitioning: a thermodynamic approach. J. Chem. Inform. Comput. Sci. 41(1), 120–128 (2001).
  Medline CASGoogle Scholar
• 66 Lobell M, Molnar L, Keseru GM. Recent advances in the prediction of blood–brain partitioning from molecular structure. J. Pharm. Sci. 92(2), 360–370 (2003).
  Medline CASGoogle Scholar
• 67 Ma XL, Chen C, Yang J. Predictive model of blood–brain barrier penetration of organic compounds. Acta Pharmacol. Sin. 26(4), 500–512 (2005).
  Medline CASGoogle Scholar
• 68 Clark DE. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood–brain barrier penetration. J. Pharm. Sci. 88(8), 815–821 (1999).
  Medline CASGoogle Scholar
• 69 Platts JA, Abraham MH, Zhao YH, Hersey A, Ijaz L, Butina D. Correlation and prediction of a large blood–brain distribution data set – an lfer study. Eur. J. Med. Chem. 36(9), 719–730 (2001).
  Medline CASGoogle Scholar
• 70 Garg P, Verma J. In silico prediction of blood brain barrier permeability: an artificial neural network model. J. Chem. Inform. Model. 46(1), 289–297 (2006).
  Medline CASGoogle Scholar
• 71 Wu ZY, Pan J, Yuan Y, Hui AL, Yang Y, Zhou A. Comparison of prediction models for blood brain barrier permeability and analysis of the molecular descriptors. Pharmazie 67(7), 628–634 (2012).
  Medline CASGoogle Scholar
• 72 Lanevskij K, Japertas P, Didziapetris R. Improving the prediction of drug disposition in the brain. Expert Opin. Drug Metabol. Toxicol. 9(4), 473–486 (2013).
  Medline CASGoogle Scholar
• 73 Fan Y, Unwalla R, Denny RA et al. Insights for predicting blood–brain barrier penetration of CNS targeted molecules using QSPR approaches. J. Chem. Inform. Model. 50(6), 1123–1133 (2010).
  Medline CASGoogle Scholar
• 74 Liu R, Sun H, So SS. Development of quantitative structure-property relationship models for early ADME evaluation in drug discovery. 2. blood–brain barrier penetration. J. Chem. Inform. Comput. Sci. 41(6), 1623–1632 (2001).
  Medline CASGoogle Scholar
• 75 Klon AE, Lowrie JF, Diller DJ. Improved naive bayesian modeling of numerical data for absorption, distribution, metabolism and excretion (ADME) property prediction. J. Chem. Inform. Model. 46(5), 1945–1956 (2006).
  Medline CASGoogle Scholar
• 76 Li H, Yap CW, Ung CY, Xue Y, Cao ZW, Chen YZ. Effect of selection of molecular descriptors on the prediction of blood–brain barrier penetrating and nonpenetrating agents by statistical learning methods. J. Chem. Inform. Model. 45(5), 1376–1384 (2005).
  Medline CASGoogle Scholar
• 77 Rishton GM, Labonte K, Williams AJ, Kassam K, Kolovanov E. Computational approaches to the prediction of blood–brain barrier permeability: a comparative analysis of central nervous system drugs versus secretase inhibitors for Alzheimer's disease. Curr. Opin. Drug Discov. Dev. 9(3), 303–313 (2006).• Descibes virtual screening of drugs by predicting their BBB permeability.
  Medline CASGoogle Scholar
• 78 Mittapalli RK, Manda VK, Adkins CE, Geldenhuys WJ, Lockman PR. Exploiting nutrient transproters at the blood–brain barrier to improve brain distribution of small molecules. Ther. Deliv. 1(6), 775–784 (2011).•• Describes the role of nutrient transporters in brain distribution of drugs.
  Google Scholar
• 79 Peura L, Malmioja K, Huttunen K et al. Design, synthesis and brain uptake of lat1-targeted amino acid prodrugs of dopamine. Pharm. Res. 30(10), 2523–2537 (2013).
  Medline CASGoogle Scholar
• 80 Peura L, Malmioja K, Laine K et al. Large amino acid transporter 1 (LAT1) prodrugs of valproic acid: new prodrug design ideas for central nervous system delivery. Mol. Pharm. 8(5), 1857–1866 (2011).
  Medline CASGoogle Scholar
• 81 Dickens D, Webb SD, Antonyuk S et al. Transport of gabapentin by lat1 (slc7a5). Biochem. Pharmacol. 85(11), 1672–1683 (2013).
  Medline CASGoogle Scholar
• 82 Koziara JM, Lockman PR, Allen DD, Mumper RJ. The blood–brain barrier and brain drug delivery. J. Nanosci. Nanotechnol. 6(9–10), 2712–2735 (2006).
  Medline CASGoogle Scholar
• 83 Allen DD, Lockman PR. The blood–brain barrier choline transporter as a brain drug delivery vector. Life Sci. 73(13), 1609–1615 (2003).
  Medline CASGoogle Scholar
• 84 Zheng G, Zhang Z, Lockman PR et al. Bis-azaaromatic quaternary ammonium salts as ligands for the blood–brain barrier choline transporter. Bioorg. Med. Chem. Lett. 20(11), 3208–3210 (2010).
  Medline CASGoogle Scholar
• 85 In situ WJ, Manda VK, Mittapalli RK et al. Predictive screening model for potential vector-mediated transport of cationic substrates at the blood–brain barrier choline transporter. Bioorg. Med. Chem. Lett. 20(3), 870–877 (2010).•• Describes predictive screening models for choline transporters.
  MedlineGoogle Scholar
• 86 Zhang Z, Lockman PR, Mittapalli RK, Allen DD, Dwoskin LP, Crooks PA. Bis-pyridinium cyclophanes: novel ligands with high affinity for the blood–brain barrier choline transporter. Bioorg. Med. Chem. Lett. 18(20), 5622–5625 (2008).
  Medline CASGoogle Scholar
• 87 Lockman PR, Manda VK, Geldenhuys WJ et al. Carrier-mediated transport of the quaternary ammonium neuronal nicotinic receptor antagonist n, n’-dodecylbispicolinium dibromide at the blood–brain barrier. J. Pharmacol. Exp. Ther. 324(1), 244–250 (2008).
  Medline CASGoogle Scholar
• 88 Geldenhuys WJ, Lockman PR, Nguyen TH et al. 3D-QSAR study of bis-azaaromatic quaternary ammonium analogs at the blood–brain barrier choline transporter. Bioorg. Med. Chem. 13(13), 4253–4261 (2005).•• Discusses various predictive models for transport assisted by transporter.
  Medline CASGoogle Scholar
• 89 Geldenhuys WJ, Lockman PR, Mcafee JH, Fitzpatrick KT, Van Der Schyf CJ, Allen DD. Molecular modeling studies on the active binding site of the blood–brain barrier choline transporter. Bioorg. Med. Chem. Lett. 14(12), 3085–3092 (2004).
  Medline CASGoogle Scholar
• 90 Ekins S, Tropsha A. A turning point for blood–brain barrier modeling. Pharm. Res. 26(5), 1283–1284 (2009).
  Medline CASGoogle Scholar